Author:
Fong Chun Yew,Gilan Omer,Lam Enid Y. N.,Rubin Alan F.,Ftouni Sarah,Tyler Dean,Stanley Kym,Sinha Devbarna,Yeh Paul,Morison Jessica,Giotopoulos George,Lugo Dave,Jeffrey Philip,Lee Stanley Chun-Wei,Carpenter Christopher,Gregory Richard,Ramsay Robert G.,Lane Steven W.,Abdel-Wahab Omar,Kouzarides Tony,Johnstone Ricky W.,Dawson Sarah-Jane,Huntly Brian J. P.,Prinjha Rab K.,Papenfuss Anthony T.,Dawson Mark A.
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Dawson, M. A., Kouzarides, T. & Huntly, B. J. Targeting epigenetic readers in cancer. N. Engl. J. Med. 367, 647–657 (2012)
2. Shi, J. & Vakoc, C. R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54, 728–736 (2014)
3. Herait, P. E. et al. BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. Cancer Res. 74, CT231 (2014)
4. Dawson, M. A. & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27 (2012)
5. Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480–488 (2013)
Cited by
450 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献